Hasil Pencarian - Sander Croes

  • Menampilkan 1 - 5 hasil dari 5
Perbaiki Hasil
  1. 1
    Vancomycin dosing in neutropenic patients.

    Vancomycin dosing in neutropenic patients. oleh Michiel B Haeseker, Sander Croes, Cees Neef, Cathrien A Bruggeman, Leo M L Stolk, Annelies Verbon

    Diterbitkan 2014-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  2. 2
    Incidence of Bone Metastases and Skeletal-Related Events in Patients With EGFR-Mutated NSCLC Treated With Osimertinib

    Incidence of Bone Metastases and Skeletal-Related Events in Patients With EGFR-Mutated NSCLC Treated With Osimertinib oleh Anita J.W. M. Brouns, MD, Ard van Veelen, MSc, G. D. Marijn Veerman, MD, Christi Steendam, MD, Safiye Dursun, MD, Cor van der Leest, PhD, Sander Croes, PhD, Anne-Marie C. Dingemans, MD, PhD, Lizza E.L. Hendriks, PhD

    Diterbitkan 2023-05-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  3. 3
    Influence of germline variations in drug transporters ABCB1 and ABCG2 on intracerebral osimertinib efficacy in patients with non-small cell lung cancerResearch in context

    Influence of germline variations in drug transporters ABCB1 and ABCG2 on intracerebral osimertinib efficacy in patients with non-small cell lung cancerResearch in context oleh G.D. Marijn Veerman, Rene J. Boosman, Merel Jebbink, Esther Oomen-de Hoop, Anthonie J. van der Wekken, Idris Bahce, Lizza E.L. Hendriks, Sander Croes, Christi M.J. Steendam, Evert de Jonge, Stijn L.W. Koolen, Neeltje Steeghs, Ron H.N. van Schaik, Egbert F. Smit, Anne-Marie C. Dingemans, Alwin D.R. Huitema, Ron H.J. Mathijssen

    Diterbitkan 2023-05-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  4. 4
    Therapeutic drug monitoring guided dosing versus standard dosing of alectinib in advanced ALK positive non-small cell lung cancer patients: Study protocol for an international, multicenter phase IV randomized controlled trial (ADAPT ALEC)

    Therapeutic drug monitoring guided dosing versus standard dosing of alectinib in advanced ALK positive non-small cell lung cancer patients: Study protocol for an international, mul... oleh Marinda Meertens, M. Benthe Muntinghe-Wagenaar, Barend J. Sikkema, Marta Lopez-Yurda, Valesca P. Retèl, Marthe S. Paats, Rob Ter Heine, Ed Schuuring, Wim Timens, Daan J. Touw, Job F. M. van Boven, Adrianus. J. de Langen, Sayed M. S. Hashemi, Lizza E. L. Hendriks, Sander Croes, Michel M. van den Heuvel, Anne-Marie C. Dingemans, Ron H. J. Mathijssen, Egbert F. Smit, Alwin D. R. Huitema, Alwin D. R. Huitema, Alwin D. R. Huitema, Neeltje Steeghs, Anthonie J. van der Wekken

    Diterbitkan 2023-03-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  5. 5
    Osimertinib Plasma Trough Concentration in Relation to Brain Metastases Development in Patients With Advanced EGFR-Mutated NSCLC

    Osimertinib Plasma Trough Concentration in Relation to Brain Metastases Development in Patients With Advanced EGFR-Mutated NSCLC oleh Judith L. Gulikers, MSc, G.D. Marijn Veerman, MD, PhD, Merel Jebbink, MD, PhD, Paul D. Kruithof, PharmD, Christi M.J. Steendam, MD, PhD, René J. Boosman, PhD, Ron H.J. Mathijssen, MD, PhD, Vivianne C.G. Tjan-Heijnen, MD, PhD, Johanna H.M. Driessen, PhD, Safiye Dursun, MD, Egbert F. Smit, MD, PhD, Anne-Marie C. Dingemans, MD, PhD, Robin M.J.M. van Geel, PharmD, PhD, Sander Croes, PharmD, PhD, Lizza E.L. Hendriks, MD, PhD

    Diterbitkan 2024-04-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:

Alat Pencarian: